← Eichor
Study identifier: NCT02594813 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Bleeding Rate After EGD and Colonoscopy in Patients Who Continue to Take Antithrombotic Agents

Condition: Bleeding After GI Endoscopy  ·  Sponsor: Showa Inan General Hospital

PhaseN/A
Planned participants10000
Who can joinAll sexes, 20 Years to 90 Years
Healthy volunteersNo

About this study

The bleeding rate of both EGD (including biopsy) and colonoscopy (including biopsy, cold or hot snare polypectomy, or EMR) in patients who continue to take various antithrombotic drugs is studied prospectively. The immediate or delayed bleeding that requires hemostatic clipping or other endoscopic treatments is defined as the bleeding. Immediate bleeding requiring hemostatic clipping is defined as spurting or oozing which continued for more than 30 seconds. Delayed bleeding is defined as bleeding that requires the endoscopic treatment within 2 weeks after endoscopy. Prophylactic clipping is not performed after taking biopsy and doing polypectomy. Additionally, investigators evaluate the rate of injured submucosal arteries of the excised specimen when the bleeding occurs.

This description comes directly from the study's public registry record.

Talk to the study team

Akira Horiuchi, MD  ·  0265822121  ·  horiuchi.akira@sihp.jp

Always discuss trial participation with your own doctor first.

Locations (1)

Showa Inan General HospitalKomagane, JapanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT02594813